Cargando...
Medical resource utilization for administration of trastuzumab in a New Zealand oncology outpatient setting: a time and motion study
BACKGROUND: In New Zealand, trastuzumab is standard therapy for human epidermal growth factor receptor-2 (HER2)-positive early and metastatic breast cancer. Given the requirement for ongoing adjuvant or maintenance treatment and intravenous (IV) delivery, such a regimen consumes considerable health...
Guardado en:
| Publicado en: | Clinicoecon Outcomes Res |
|---|---|
| Autores principales: | , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Dove Medical Press
2015
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4524269/ https://ncbi.nlm.nih.gov/pubmed/26251623 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CEOR.S85599 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|